BASEL, Switzerland, June 11, 2026
Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) and Tecentriq Hybreza® in combination with chemotherapy for the treatment of stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer following surgery. The regulatory milestone is based on compelling results from the landmark Phase III ATOMIC study, which demonstrated that the addition of Tecentriq to standard chemotherapy reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone. If approved, the immunotherapy-based regimen could become a new standard of care for patients with this genetically defined form of early-stage colon cancer, addressing a significant unmet need in a population still at substantial risk of relapse despite surgery and chemotherapy.
ATOMIC Study Delivers Landmark Reduction in Recurrence Risk
The FDA’s Priority Review designation follows the successful completion of the Phase III ATOMIC trial, one of the most important studies conducted in early-stage colorectal cancer. The trial enrolled 712 patients with stage III dMMR colon cancer and evaluated the addition of Tecentriq to standard FOLFOX6 chemotherapy following surgery. Results showed that combining immunotherapy with chemotherapy reduced the risk of disease recurrence or death by 50%, representing a major advancement in the treatment of this high-risk patient population.
The study also reported a 36-month disease-free survival rate of 86% for patients receiving Tecentriq plus chemotherapy, compared with 76% for those receiving chemotherapy alone. These findings, recently published in The New England Journal of Medicine, highlight the growing impact of precision oncology approaches that tailor treatment according to the molecular characteristics of a patient’s tumor. Importantly, the safety profile observed in the study was consistent with the well-established profiles of both Tecentriq and FOLFOX6 chemotherapy, with no unexpected safety concerns identified.
Immunotherapy Could Transform Early-Stage Colon Cancer Care
Advertisement
Colon cancer remains one of the most common and deadly cancers worldwide, with more than one million new cases diagnosed annually. Despite advances in surgery and chemotherapy, approximately 30% of patients with stage III disease experience recurrence within five years, emphasizing the urgent need for more effective adjuvant treatment strategies. Approximately 15% of colon cancer patients harbor dMMR/MSI-H tumors, a subgroup characterized by high mutation rates that may be particularly responsive to immune checkpoint inhibition.
Tecentriq, a PD-L1-targeted monoclonal antibody, is designed to reactivate the body’s immune response against cancer cells by blocking inhibitory signaling pathways that tumors use to evade immune detection. The ATOMIC results suggest that introducing immunotherapy earlier in the treatment journey may significantly improve long-term outcomes and help more patients remain cancer-free after surgery. Experts believe the findings could reshape treatment paradigms and accelerate the adoption of biomarker-driven approaches in early-stage colorectal cancer management.
FDA Decision Expected in October as Global Filings Advance
With Priority Review status now granted, the FDA is expected to complete its review and issue a decision by October 9, 2026. Roche is also pursuing additional regulatory submissions globally, including with the European Medicines Agency (EMA), as it seeks to expand access to this potentially practice-changing treatment approach. The ATOMIC study was sponsored by the National Cancer Institute (NCI) and conducted through the Alliance for Clinical Trials in Oncology in collaboration with Roche and international research partners, underscoring the importance of academic-industry partnerships in advancing cancer care.
For Roche, the filing represents another significant milestone in its expanding immuno-oncology portfolio and reinforces the company’s commitment to developing innovative therapies that improve outcomes across multiple cancer types. If approved, Tecentriq would become the first immunotherapy-based adjuvant treatment option specifically indicated for stage III dMMR/MSI-H colon cancer, potentially offering thousands of patients a better chance of long-term disease-free survival and reduced risk of relapse following curative surgery.
Source: Roche press release
